Eugenol / PARP Cancer Research Results

Eug, Eugenol: Click to Expand ⟱
Features:

Eugenol — Eugenol is a naturally occurring phenylpropanoid and volatile aromatic phenol most strongly associated with clove oil from Syzygium aromaticum. Eugenol is a phenolic aromatic ingredient that is chiefly derived from clove oil. It is formally classified as a small-molecule phytochemical, essential-oil constituent, food-flavouring agent, and experimental anticancer adjunct rather than an approved oncology drug. Standard abbreviations include EUG and 4-allyl-2-methoxyphenol. It is also present in cinnamon, basil, bay, nutmeg, and other aromatic plants. The oncology evidence is mainly preclinical, with strongest support for apoptosis induction, PI3K/Akt suppression, anti-metastatic effects, and chemo/radiosensitization in cell and animal models. clove oil has been advertised as a dental pain-relieving agent and germicide, and is used in mouthwashes and pharmaceutical drugs. Eugenol (4-allyl (-2-mthoxyphenol)), a phenolic natural compound available in honey and in the essential oils of different spices such as Syzgium aromaticum (clove), Pimenta racemosa (bay leaves), and Cinnamomum verum (cinnamon leaf).
-eugenol is the major ingredient of three spices (i.e. clove, cinnamon,and nutmeg)
-clear to pale yellow liquid with an oily consistency and a spicy aroma. It is sparingly soluble in water and well soluble in organic solvents.
-entering the systemic circulation within 30-60 minutes, paradoxically limits it therapeutic effectiveness.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis through mitochondrial dysfunction, Bax/Bcl-2 shift, cytochrome-c release, caspase activation, and PARP cleavage.
  2. Suppression of PI3K/Akt/mTOR and related survival signalling, including FOXO3a-linked autophagy/apoptosis in breast cancer models.
  3. Anti-inflammatory transcriptional modulation, especially ↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling, and context-dependent STAT3/IL-6 axis suppression.
  4. Anti-metastatic and anti-invasive activity through ↓ MMP-2/MMP-9, ↓ migration, ↓ invasion, and reduced epithelial-mesenchymal transition markers in selected models.
  5. Anti-angiogenic effects through ↓ VEGF-linked signalling and reduced invasion/angiogenesis markers in gastric and other cancer models.
  6. ROS redox modulation with model-dependent pro-oxidant stress in cancer cells and antioxidant/anti-inflammatory effects in non-malignant contexts.
  7. Chemosensitization and radiosensitization, reported preclinically with cisplatin, gemcitabine, and ionizing radiation, but not clinically established.

Bioavailability / PK relevance: Eugenol is rapidly absorbed and extensively metabolized, mainly through conjugation pathways, so systemic exposure is transient and formulation-dependent. Its volatility, lipophilicity, rapid metabolism, and local irritation risk make delivery strategy important. Nanoemulsions, encapsulation, and conjugated delivery systems are being explored preclinically to improve stability, exposure, and tumour delivery.

In-vitro vs systemic exposure relevance: Many in-vitro anticancer studies use micromolar-to-high-micromolar concentrations that may exceed freely achievable systemic exposure after ordinary dietary or flavouring-level intake. Low-dose mechanistic reports exist in some breast cancer models, but translation remains uncertain. Essential-oil or clove-derived exposure should not be equated with purified eugenol pharmacology because source composition, dose, and route strongly affect exposure.

Clinical evidence status: Preclinical. Eugenol has cell-line and animal-model anticancer evidence, plus limited adjunctive clinical-context use in aromatherapy or topical/dental products, but there is no established clinical evidence supporting eugenol as a cancer treatment. Registry-visible oncology studies involving essential oils generally assess symptom support or mixtures, not purified eugenol as an anticancer therapeutic.

Eugenol Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis and caspases ↑ Bax, ↑ cytochrome-c, ↑ caspase-3/8/9, ↓ Bcl-2, ↓ PARP integrity Mixed; cytoprotection at low exposure but irritation/cytotoxicity at high exposure R/G Apoptotic tumour-cell killing Core and most reproducible anticancer axis across breast, cervical, gastric, lung, and other models.
2 PI3K Akt mTOR survival signalling ↓ PI3K/Akt, ↓ mTOR signalling, ↑ FOXO3a activity, ↑ autophagy/apoptosis Context-dependent R/G Reduced survival signalling and increased treatment vulnerability Highly relevant in breast cancer and lung cancer models; may overlap with HER2/PI3K-Akt effects.
3 NF-κB COX-2 inflammatory signalling ↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling ↓ inflammatory signalling in non-malignant inflammatory contexts R/G Anti-inflammatory and anti-survival transcriptional pressure Important bridge between anticancer and general anti-inflammatory pharmacology.
4 MMP invasion and metastasis ↓ MMP-2, ↓ MMP-9, ↓ migration, ↓ invasion Context-dependent G Anti-invasive and anti-metastatic activity Mechanistically meaningful for breast, fibrosarcoma, gastric, and lung cancer models.
5 Angiogenesis and VEGF-linked signalling ↓ VEGF-linked angiogenic markers, ↓ invasion-associated vascular support Context-dependent; excessive exposure may irritate tissues G Reduced tumour vascularization support Best supported in animal carcinogenesis and metastasis-associated models rather than clinical oncology.
6 Cell cycle arrest ↑ p21, ↑ p27, ↓ cyclin-linked proliferation, S-phase or G2/M effects depending on model Context-dependent G Reduced proliferation Secondary but common contributor to antiproliferative activity.
7 Mitochondrial ROS redox stress ↑ ROS or redox stress in some cancer models; antioxidant effects in others Often ↓ oxidative stress at low exposure; irritation or toxicity possible at high exposure P/R/G Context-dependent redox modulation Do not tag simply as antioxidant. Cancer-cell effect can be pro-oxidant, antioxidant, or mixed depending on dose, timing, and model.
8 NRF2 antioxidant response Mixed or context-dependent; not a primary anticancer-defining axis Potential ↑ cytoprotective antioxidant response in non-malignant stress models G Secondary redox adaptation Include only as secondary/contextual unless a specific study demonstrates NRF2-dependent cancer-cell modulation.
9 Glycolysis and metabolic reprogramming Metabolomic shifts reported; likely ↓ proliferative metabolic fitness in selected CRC/oral cancer contexts Unclear G Metabolic stress Mechanistically interesting but less mature than apoptosis, PI3K/Akt, and invasion axes.
10 Chemosensitization ↑ cisplatin cytotoxicity, ↑ gemcitabine activity, ↑ apoptosis Potential normal-cell toxicity not adequately defined R/G Adjunctive treatment sensitization Preclinical only; promising but insufficient for clinical-use claims.
11 Radiosensitization ↑ ionizing-radiation cytotoxicity in cervical and oral cancer models Normal-tissue protection versus sensitization remains unresolved R/G Radiation response enhancement Preclinical only; should be tagged as experimental radiosensitizer, not clinically validated.
12 Clinical Translation Constraint In-vitro exposure may exceed realistic free systemic levels High-dose clove oil/eugenol can irritate mucosa and has overdose hepatotoxicity risk G Limits direct translation Major constraints are rapid metabolism, dose-limited tolerability, formulation dependence, lack of oncology trials, and distinction between food-level GRAS use and therapeutic dosing.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
6388- Eug,    Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review
- Review, Var, NA
Dose↝, AntiCan↑, *Inflam↓, *cardioP↑, *neuroP↑, angioG↓, TumMeta↓, *BioAv↑, *eff↑, *toxicity↝, antiNeop↑, TumCCA↑, Apoptosis↑, *antiOx↑, *lipid-P↓, *ROS↓, *SOD↑, *Catalase↑, *GSTs↑, *GPx↑, *iNOS↓, *COX2↓, *IL6↓, *TNF-α↓, *AntiArt↑, *Bacteria↓, TumAuto↑, PI3K↓, Akt↓, FOXO3↝, BAX↑, mTOR↓, NF-kB↓, P53↑, TumCG↓, CSCs↓, CD44↓, EpCAM↓, NOTCH1↓, OCT4↓, Bcl-2↓, PDK1↓, HER2/EBBR2↓, BAD↓, cycD1/CCND1↓, ROS↑, Casp3↑, selectivity↑, MMP2↓, MMP9↓, TIMP1↑, VEGF↓, VEGFR1↓, RECK↑, TIMP2↑, DNAdam↑, MMP↓, Thiols↓, PARP↑, *Pain↓, E2Fs↓, survivin↓,
6389- Eug,    Molecular Insights into the Management of Eugenol's Anticancer Action Against Colon Cancer: A Detailed Review
- Review, Colon, NA
Apoptosis↓, TumCCA↓, Inflam↓, TumMeta↓, BioAv↑, eff↓, Half-Life↓, *ROS↓, *RNS↓, *SOD↓, *Catalase↑, *GSTs↑, *MAOA↓, *neuroP↑, *DNAdam↓, Apoptosis↑, ROS↑, selectivity↑, MMP↓, Cyt‑c↓, Casp3↑, Casp9↑, TumCD↑, BAX↑, BAD↑, APAF1↑, Bcl-2↓, Bcl-xL↓, P53↑, cl‑PARP↑, TumCCA↑, cycD1/CCND1↓, CycB/CCNB1↓, CDK2↓, CDK4↓, P21↑, p27↑, NF-kB↓, COX2↓, PGE2↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, MMPs↓, EMT↓, Snail↓, Slug↓, Zeb1↓, E-cadherin↑, ChemoSen↑,
6390- Eug,    Molecular mechanisms of eugenol as an antitumour bioactive compound: A comprehensive review
- Review, Var, NA
TumCCA↑, angioG↓, TumMeta↓, tumCV↓, Casp3↑, Casp6↑, DFF45↑, PARP↑, ROS↑, Cyt‑c↑, MPT↑, *ROS↓, NF-kB↓, COX2↓, 5LO↓, EMT↓, Snail↓, E-cadherin↑, Vim↓, PI3K↓, Akt↓, mTORC2↓, TumAuto↑, FOXO3↓, Apoptosis↑, ChemoSen↑, RadioS↑, DNMT1↓, DNMT3A↓,
6325- Eug,    Anticancer Properties of Eugenol: A Review
- Review, Var, NA
*antiOx↑, *AntiCan↑, *Inflam↓, TumCD↑, TumCCA↑, TumCMig↓, TumMeta↓, angioG↓, ChemoSen↑, chemoP↑, *BioAv↝, *BioAv↑, *BioAv↑, *BioAv↑, *Bacteria↓, *ROS↓, *IL6↓, *COX2↓, *TNF-α↓, *lipid-P↓, *SOD1↑, *Catalase↑, *GPx1↑, *GSTs↑, ROS↑, MMP↓, Apoptosis↑, COX2↓, TumCCA↑, E2Fs↓, PI3K↓, Akt↓, MMPs↓, CSCs↓, OCT4↓, CD44↓, EpCAM↓, NOTCH1↓, TumVol↓, Casp3↑, P53↑, cl‑PARP↑, MMP2↓, MMP9↓, TIMP1↑, ALDH↓, NF-kB↓, *toxicity↓,
6330- Eug,    Molecular Mechanisms of Action of Eugenol in Cancer: Recent Trends and Advancement
- Review, Var, NA
TumCD↑, TumCCA↑, AntiCan↑, Apoptosis↑, angioG↓, TumCI↓, TumMeta↓, ChemoSen↑, ALDH↓, NF-kB↓, IL6↓, IL8↓, BAX↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, Bcl-2↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Snail↓, E-cadherin↑, SOX2↓, ROS↑, PCNA↓, MMP1↓, Cyt‑c↑, LDH↑, CSCs↓, OCT4↓, NOTCH1↓, EpCAM↓, CD44↓, HER2/EBBR2↓, VEGF↓, TIMP2↑, eff↑, Ca+2↑, TumVol↓, DNAdam↑, GSH↓, H2O2↑, lipid-P↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   H2O2↑, 1,   lipid-P↑, 1,   ROS↑, 5,   Thiols↓, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 3,   MPT↑, 1,  

Core Metabolism/Glycolysis ⓘ

LDH↑, 1,   PDK1↓, 1,  

Cell Death ⓘ

Akt↓, 4,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 5,   BAD↓, 1,   BAD↑, 1,   BAX↑, 3,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp6↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 2,   MAPK↓, 1,   p27↑, 1,   survivin↓, 1,   TumCD↑, 3,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 2,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DFF45↑, 1,   DNAdam↑, 2,   DNMT1↓, 1,   DNMT3A↓, 1,   P53↑, 3,   PARP↑, 2,   cl‑PARP↑, 3,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   E2Fs↓, 2,   P21↑, 1,   TumCCA↓, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 2,   CD44↓, 3,   CSCs↓, 3,   EMT↓, 3,   EpCAM↓, 3,   FOXO3↓, 1,   FOXO3↝, 1,   mTOR↓, 2,   mTORC2↓, 1,   NOTCH1↓, 3,   OCT4↓, 3,   PI3K↓, 4,   SOX2↓, 1,   TumCG↓, 1,  

Migration ⓘ

5LO↓, 1,   Ca+2↑, 1,   E-cadherin↑, 3,   MMP1↓, 1,   MMP2↓, 3,   MMP9↓, 3,   MMPs↓, 2,   N-cadherin↓, 1,   RECK↑, 1,   Slug↓, 1,   Snail↓, 3,   TIMP1↑, 2,   TIMP2↑, 2,   TumCI↓, 1,   TumCMig↓, 1,   TumMeta↓, 5,   VEGFR1↓, 1,   Vim↓, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 5,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 4,   Dose↝, 1,   eff↓, 1,   eff↑, 1,   Half-Life↓, 1,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

HER2/EBBR2↓, 2,   IL6↓, 1,   LDH↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   antiNeop↑, 1,   chemoP↑, 1,   TumVol↓, 2,  
Total Targets: 104

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiArt↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 3,   GPx↑, 1,   GPx1↑, 1,   GSTs↑, 3,   lipid-P↓, 2,   RNS↓, 1,   ROS↓, 4,   SOD↓, 1,   SOD↑, 1,   SOD1↑, 1,  

Cell Death ⓘ

iNOS↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL6↓, 2,   Inflam↓, 2,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

MAOA↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 4,   BioAv↝, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   neuroP↑, 2,   Pain↓, 1,   toxicity↓, 1,   toxicity↝, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 2,  
Total Targets: 30

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
5 Eugenol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:399  Target#:239  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page